TerminatedInterventionalPhase 2Updated Oct 25, 2013
Safety and Intraocular Pressure (IOP)-Lowering Efficacy of AL-39256 in Patients With Open-Angle Glaucoma or Ocular Hypertension | NCT00761709 | Trialant
Safety and Intraocular Pressure (IOP)-Lowering Efficacy of AL-39256 in Patients With Open-Angle Glaucoma or Ocular Hypertension
ClinicalTrials.gov ID
NCT00761709
Lead Sponsor
Alcon ResearchINDUSTRY
Overall Status
Completed
Study Type
Interventional
Phase
Phase 2
Enrollment
104Actual
Last Update Posted
Jul 15, 2014Estimated
Start Date
Jul 2009
Primary Completion Date
Oct 2009Actual
Completion Date
Oct 2009Actual
Brief Summary
The purpose of this study is to evaluate the safety and intraocular pressure (IOP)-lowering efficacy of AL-39256 in patients with open-angle glaucoma or ocular hypertension.
Open-Angle Glaucoma
Ocular Hypertension
AL-39256 Ophthalmic Suspension, 1%
Latanoprost Ophthalmic Solution, 0.005%
Vehicle
Ages Eligible for Study
Adult (18-64)Older Adult (65+)
Sexes Eligible for Study
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Diagnosed with open-angle glaucoma or ocular hypertension.
Other protocol-defined inclusion criteria may apply.
Exclusion Criteria:
Females of childbearing potential.
Other protocol-defined exclusion criteria may apply.